# The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

> **NCT05532800** · PHASE3 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 255 (actual)

## Conditions studied

- Hyperlipemia

## Interventions

- **DRUG:** JS002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05532800
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532800, "The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05532800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*